The Effect of Dextran of Various Molecular Weight on the Coagulation in Dogs

Sven Erik Bergentz; Oddvar Eiken; Inga Marie Nilsson

doi:10.1055/s-0038-1654535

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1961; 6(01): 015-024
DOI: 10.1055/s-0038-1654535

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

The Effect of Dextran of Various Molecular Weight on the Coagulation in Dogs

Sven Erik Bergentz

¹Department of Surgery II, University of Göteborg, Sahlgrenska Sjukhuset, Göteborg; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö, Sweden

,

Oddvar Eiken

¹Department of Surgery II, University of Göteborg, Sahlgrenska Sjukhuset, Göteborg; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö, Sweden

,

Inga Marie Nilsson

¹Department of Surgery II, University of Göteborg, Sahlgrenska Sjukhuset, Göteborg; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö, Sweden

› Author Affiliations

Abstract

Summary

1. Infusions of low molecular weight dextran (M_w = 42 000) to dogs in doses of 1—1.5 g per kg body weight did not produce any significant changes in the coagulation mechanism.

2. Infusions of high molecular weight dextran (M_w = 1 000 000) to dogs in doses of 1—1.5 g per kg body weight produced severe defects in the coagulation mechanism, namely prolongation of bleeding time and coagulation time, thrombocytopenia, pathological prothrombin consumption, decrease of fibrinogen, prothrombin and factor VII, factor V and AHG.

3. Heparin treatment of the dogs was found to prevent the decrease of fibrinogen, prothrombin and factor VII, and factor V otherwise occurring after injection of high molecular weight dextran. Thrombocytopenia was not prevented.

4. In in vitro experiments an interaction between fibrinogen and dextran of high and low molecular weight was found to take place in systems comprising pure fibrinogen. No such interaction occurred in the presence of plasma.

5. It is concluded that the coagulation defects induced by infusions of high molecular weight dextran are due to intravascular coagulation.

Full Text

References

References
(1) Adant M. Quelques effets de l’injection intraveineuse de dextran et de polyvinylpyrrolidone au chien normal ou hépatectomisé. Bull. Acad. roy. Méd. Belg. 19: 264 1954;
(2) Adelson E. Bleeding time prolongation after dextran infusion. Bibl. haemat (Basel) 7: 275 1958;
(3) Adelson E, Crosby W. H, Roeder W. H. Further studies of a hemostatic defect caused by intravenous dextran. J. Lab. clin. Med. 45: 441 1955;
(4) Bergentz S.-E, Nilsson I. M. Changes in coagulation and fibrinolysis occurring in dogs after trauma. Acta chir. scand.. In press 1961
(5) Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark. Kemi 10: 415 1956;
(6) Bronwell A. W, Artz C. P, Sako Y. Evaluation of blood loss from standardized wound after dextran. Surg. Forum 5: 809 1954;
(7) Carbone T. V, Furth F. W, Scoll Jr R, Crosby W. H. An haemostatic defect associated with dextran infusion. Proc. Soc. exp. Biol. (N. Y.) 85: 101 1954;
(8) Ellis Jr P, Kleinsasser R, LeRoy J, Speer R. J. Changes in coagulation occurring in dogs during hypothermia and cardiac surgery. Surgery 41: 198 1957;
(9) Fletcher F, Martin L, Ratcliffe A. Interaction of macromolecules and fibrinogen. Nature 170: 319 1952;
(10) Gelin L. E. Studies in anemia of injury. Acta dur. scand. Suppl. 210 1956;
(11) Howard J. M, Teng C. T, Loeffler R. K. Studies of dextrans of various molecular sizes. Ann. Surg. 143: 369 1956;
(12) Horvath S. M, Hamilton L. H, Spurr G. B, Allbaugh E. B, Hutt B. K. Plasma expanders and bleeding times. J. appl. Physiol. 7: 614 1954;
(13) Hummel K, Halse T. Theoretische Grundlagen der blutstillenden Wirkung von Kolloiden. Klin. Wschr. 30: 688 1952;
(14) Jacobaeus U. The effect of dextran on the coagulation of blood. Acta med. scand. 6: 505 1955;
(15) Jacobaeus U. Studies on the effect of dextran on the coagulation of blood. Acta med. scand. Suppl. 157 1957;
(16) Jaenike J, Waterhouse C. Metabolic and hemodynamic changes induced by the prolonged administration of dextran. Circulation 11: 1 1955;
(17) Langdell R. D, Adelson E, Furth F. W, Crosby W. H. Dextran and prolonged bleeding time. J. Amer. med. Ass. 166: 346 1958;
(18) Laurell A. B. Influence of dextran on the conversion of fibrinogen to fibrin. Scand. J. clin. Lab. Invest. 3: 262 1951;
(19) Long D, Sanches L, Vareo R. L, Lillehei W. The use of Low Molecular Weight Dextran and Serum Albumin as plasma expanders in Extracorporeal Circulation. To be published.
(20) Nilsson I. M, Blombäck M, Francken I. v. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta med. scand. 159: 35 1957;
(21) Nilsson I. M, Olow B. Streptokinase induced fibrinolysis in man. Acta chir. scand.. To be published.
(22) Nilsson I. M, Sjoerdsma A, Waldenström J. Antifibrinolytic activity and metabolism of ε-aminocaproic acid in man. Lancet 1: 1322 1960;
(23) Ricketts C. R. Interaction of dextran and fibrinogen. Nature 169: 970 1952;
(24) Ross S, Ebert R. Microelectrophoresis of blood platelets and the effects of dextran. J. clin. Invest. 38: 155 1959;
(25) Rothman S, Adelson E, Schwebel A, Langdell R. D. Adsorption of carbon-14 dextran to human blood platelets and red blood cells, in vitro. Vox Sang. (Basel) 2: 104 1957;
(26) Scott J. S. Blood coagulation failure in obstetrics. Brit. med. J. 2: 290 1955;
(27) Semple R. The effects of single large infusions of various dextran solutions on hypovolemic dogs. Canad. J. Biochem. 32: 670 1954;
(28) Semple R. Changes in protein fractions of dog plasma after bleeding and dextran infusion. J. Lab. clin. Med. 45: 61 1955;
(29) Swank R. Suspension stability of the blood after injections of dextran. J. appi. Physiol. 12: 125 1958;